Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the playbook in terms of sourcing cellular material for advanced therapies manufacture. So how might therapy developers benefit from the unique abilities of stem cells? And will they live up to their expectations?

To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

Marinna Madrid
Marinna Madrid is a co-founder at Cellino, a venture capital-backed biotech company building the next generation of cell-based tissues and therapies with a proprietary platform technology. Marinna earned her PhD and MA in Applied Physics from Harvard University, where she played a significant role in co-inventing laser-based intracellular delivery techniques. Prior to her graduate studies, she completed her BSc in Biophysics at the University of California, Los Angeles, having initially started her academic journey at Riverside Community College. In addition to receiving honors for her achievevements, including the Harvard Graduate Prize Fellowship, she also earned a spot on the Forbes 30 Under 30 list for Healthcare in 2019. 

Adil Duru
Adil Duru is a Senior Research Manager at Glycostem Therapeutics. Glycostem Therapeutics is a Dutch biotech company established in 2007 that focuses on the development of Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. Adil's main research and development interest is exploring novel NK cell and T cell based cancer immunotherapy approaches including genetically engineered NK cells and T cells.